Riskpilot← Back to searchSign inGet full accessCEPHALON A/S
A/SActiveCVR 20009993Sundsholmen 29Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199717 employees
Revenue 2025
DKK 17,4M
-9% vs 2024
EBITDA margin
25.1%
-27% vs 2024
Equity ratio
61.1%
Financial strength
Net profit 2025
DKK 3,3M
-24% vs 2024
| Revenue | DKK 17,4M | -9% |
| EBITDA | DKK 4,4M | -27% |
| Net profit | DKK 3,3M | -24% |
| Total assets | DKK 33,8M | +10% |
| Equity | DKK 20,6M | -3% |
| Employees | 17 | — |
Legal name
CEPHALON A/S
CVR number
20009993
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
6. maj 1997
Share capital
DKK 500.000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsens formand, et bestyrelsesmedlem i forening med bestyrelsens formand eller af den samlede bestyrelse i forening.
Company purpose
Selskabets formål er at drive handelsvirksomhed samt hermed efter bestyrelsens skøn beslægtet virksomhed.
Address
Sundsholmen 29
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.425 | 16.043 | 18.595 | 19.422 | 18.071 | 15.704 | 12.532 | 12.761 | 12.690 | 14.672 | 17.205 | 23.862 | 19.216 | 17.447 |
| Staff expenses | -9.322 | -9.670 | -10.579 | -12.470 | -12.204 | -11.530 | -11.801 | -11.722 | -10.240 | -10.998 | -11.590 | -13.593 | -13.201 | -13.069 |
| EBITDA | 7.103 | 6.373 | 8.016 | 6.952 | 5.867 | 4.174 | 731 | 994 | 2.450 | 3.674 | 5.614 | 10.260 | 6.015 | 4.378 |
| Depreciation & amort. | -651 | -686 | -468 | -56 | -143 | -25 | -44 | -76 | -97 | -102 | -102 | -158 | -253 | -246 |
| EBIT | 6.452 | 5.686 | 7.548 | 6.896 | 5.724 | 4.149 | 686 | 918 | 2.353 | 3.572 | 5.512 | 10.102 | 5.761 | 4.133 |
| Net financials | -21 | -22 | 67 | 74 | -103 | -33 | -40 | -41 | -58 | -85 | -652 | 722 | -264 | 64 |
| Profit before tax | 6.431 | 5.664 | 7.615 | 6.970 | 5.621 | 4.116 | 646 | 877 | 2.295 | 3.488 | 4.860 | 10.824 | 5.498 | 4.197 |
| Tax | 1.616 | 1.472 | 1.906 | 1.483 | 1.189 | 888 | 114 | 193 | 505 | 772 | 1.072 | 2.398 | 1.221 | 935 |
| Net profit | 4.829 | 4.213 | 5.687 | 5.486 | 4.432 | 3.228 | 532 | 684 | 1.789 | 2.715 | 3.788 | 8.427 | 4.277 | 3.261 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 27.294 | 22.285 | 32.760 | 30.595 | 26.434 | 28.634 | 23.199 | 21.478 | 25.978 | 26.005 | 31.994 | 30.508 | 30.772 | 33.794 |
| Equity | 13.079 | 13.292 | 15.979 | 18.465 | 18.897 | 19.125 | 16.657 | 16.740 | 17.879 | 16.595 | 17.683 | 23.109 | 21.386 | 20.648 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 14.069 | 8.972 | 16.760 | 12.109 | 7.517 | 9.502 | 6.542 | 4.718 | 8.072 | 9.390 | 14.302 | 7.371 | 9.373 | 13.147 |
| Total debt | 14.069 | 8.972 | 16.760 | 12.109 | 7.517 | 9.502 | 6.542 | 4.718 | 8.072 | 9.390 | 14.302 | 7.371 | 9.373 | 13.147 |
EBITDA margin
25.1%
This company
15.8%
Market median
+59% vs market
20122025
Equity ratio
61.1%
This company
38.2%
Market median
+60% vs market
20122025
Return on equity
15.8%
This company
18.4%
Market median
+14% vs market
20122025
Net profit margin
18.7%
This company
8.1%
Market median
+131% vs market
20122025
Asset turnover
0.52×
This company
1.12×
Market median
-54% vs market
20122025
Debt / equity
0.64×
This company
0.62×
Market median
+3% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RN Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1997 | — | — | |
| Board of Directors | 1997 | — | — | |
| Chairman | 2007 | — | — | |
| Board of Directors | 1997 | — | — | |
| Board of Directors | 2007 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2007 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CEPHALON A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nejsum | Chief Executive Officer | 0 companies |
| Klaus Erik Johansen | Board of Directors | 0 companies |
| Hans Steen Andreassen | Board of Directors | 0 companies |
| Bjørn Helmer Johnsen | Chairman | 0 companies |
| Susanne Svejgaard Johansen | Board of Directors | 0 companies |
| Erling Henningsen | Board of Directors | 0 companies |